Full-Time

Director Quality Analytical Technical Lead

Small Molecule

Updated on 9/3/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$168k - $228k/yr

+ Incentive compensation plan + Discretionary equity awards + Employee Stock Purchase Plan

Remote in USA

Remote

Travel up to 20% may be required.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
GMP
Word/Pages/Docs
Risk Management
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to BeOne

See people who can refer or advise you

Requirements
  • A bachelor's degree and 10 or more years of biopharmaceutical experience with significant commercial lifecycle responsibility experience.
  • Strong PC literacy and proficiency with Microsoft Office applications, including Outlook, Word, Excel, and PowerPoint.
  • Demonstrated leadership in good manufacturing practice quality control and/or analytical sciences for small-molecule methods, including high-performance liquid chromatography/ultra-performance liquid chromatography, gas chromatography, dissolution, residual solvents, elemental impurities, and genotoxic impurities as applicable.
  • Strong working knowledge of method validation and verification, stability trends and statistical evaluation, specification lifecycle management, and data integrity.
  • Ability to lead through influence in a matrix organization, with stakeholder management and negotiation skills.
  • Strong technical writing skills and the ability to deliver inspection-defensible narratives.
  • A program and risk management mindset, with the ability to prioritize in supply-constrained environments.
Responsibilities
  • Act as the global point of contact for all analytical-related matters for assigned products to ensure analytical readiness.
  • Provide governance and technical leadership for analytical topics spanning drug substance, drug product, and critical raw materials and reagents as applicable.
  • Translate global product strategy into aligned expectations and deliverables for internal quality control sites, external quality control laboratories and contract manufacturing organizations, analytical science and technology, and manufacturing science and technology.
  • Lead and approve strategies for analytical investigations and performance issues, including out-of-specification, out-of-trend, out-of-expectation, atypical results, and invalidations, ensuring scientifically sound root-cause analysis and effective corrective and preventive action, including method optimization.
  • Drive analytical change-control impact assessments and execution plans, including method updates, revalidation or verification, reference-standard changes, and instrument or software upgrades.
  • Own escalation management for supply-critical analytical events and align actions with Quality, Regulatory, and Supply Chain.
  • Serve as the global business-process and knowledge owner for commercial analytical method lifecycle management, global specifications governance, stability programs, and retest-period and shelf-life governance.
  • Take over submission-ready documentation sources from development, including analytical control strategy, method history, validation packages, specification rationale, and stability-trend narratives.
  • Ensure defensible alignment between the analytical control strategy and product risk profile, including critical quality attributes, critical process parameters, and small-molecule impurity control.
  • Provide analytical subject-matter-expert leadership for Rest of World filings and post-approval changes, including Module 3 analytical sections, stability commitments, method and specification alignment, variations, supplements, comparability narratives, and analytical bridging.
  • Partner with Regulatory Chemistry, Manufacturing, and Controls on health-authority interactions and responses related to analytical controls, stability trends, and specification justification.
  • Provide governance for external quality-control networks by aligning expectations, metrics, investigation quality, and issue-escalation pathways.
  • Contribute to audits and inspections as the product analytical subject-matter expert and ensure inspection readiness for assigned products and analytical systems.
  • Influence laboratory capacity planning and capability upgrades using a risk-based approach.
Desired Qualifications
  • A master's degree and 7 or more years of biopharmaceutical experience with significant commercial lifecycle responsibility experience.
  • A doctoral degree and 5 or more years of biopharmaceutical experience with significant commercial lifecycle responsibility experience.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

-9%

2 year growth

-3%
Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.

PR Newswire
Jul 21st, 2026
Seegene USA receives FDA emergency authorisation for first multiplex PCR test to diagnose viral causes of ulcerative skin lesions

Seegene USA has received Emergency Use Authorization from the FDA for its Allplex HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR test that simultaneously detects herpes simplex virus types 1 and 2, varicella-zoster virus, and monkeypox virus. It is the first multiplex PCR test designed to support differential diagnosis of viral causes of ulcerative skin lesions in the US market. These pathogens often present with similar clinical symptoms that are difficult to distinguish visually. Research presented at the 2024 Clinical Virology Symposium found that a multiplex PCR assay identified HSV, VZV, or MPXV in 54 out of 966 samples that had previously tested negative using single-pathogen methods. The assay was developed using Seegene's proprietary multiplex PCR technologies and automated product development platform.